Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zogenix, Inc.

https://www.zogenix.com/

Latest From Zogenix, Inc.

FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle

Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.

M & A Commercial

UCB's Zogenix Bet Pays Out Quickly With Fresh Fintepla Approval

Gaining approval for Fintepla in Lennox-Gastaut syndrome, on top of an earlier green light in Dravet, puts the Belgian group in a strong position to compete with Jazz’s Epidiolex.

Approvals Neurology

The Short And Controversial Life Of Zohydro Comes To An End

US FDA’s approval of the opioid over resounding opposition of an advisory committee has haunted the agency, and it has imperiled both of Robert Califf’s nominations to be commissioner. The latest company to own Zohydro stopped selling it and FDA withdrew approval of its NDA.

FDA Regulation

Stock Watch: Biogen, Blood In The Water

When almost everything that could go wrong has gone wrong at a company, the proposition of it turning acquirer may meet with some resistance from its proposed targets and their investors.

Stock Watch M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Brabant Pharma, Modis Therapeutics, Inc. Zogenix International, Ltd. Zogenix Europe Limited
UsernamePublicRestriction

Register